119 related articles for article (PubMed ID: 34896436)
21. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
23. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma.
Yellapu NK; Pulaganti M; Pakala SB
J Biomol Struct Dyn; 2017 Aug; 35(10):2269-2279. PubMed ID: 27456030
[TBL] [Abstract][Full Text] [Related]
25. Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy.
Zhu QN; Renaud H; Guo Y
Hereditas; 2018; 155():17. PubMed ID: 29371858
[TBL] [Abstract][Full Text] [Related]
26. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells.
Akinmade D; Talukder AH; Zhang Y; Luo WM; Kumar R; Hamburger AW
Br J Cancer; 2008 Mar; 98(6):1132-40. PubMed ID: 18283314
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
29. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
[TBL] [Abstract][Full Text] [Related]
30. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer.
Gong C; Tsoi H; Mok KC; Cheung J; Man EPS; Fujino K; Wong A; Lam EWF; Khoo US
Oncogene; 2020 Apr; 39(15):3206-3217. PubMed ID: 32066877
[TBL] [Abstract][Full Text] [Related]
32. Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.
Wei C; Cao Y; Yang X; Zheng Z; Guan K; Wang Q; Tai Y; Zhang Y; Ma S; Cao Y; Ge X; Xu C; Li J; Yan H; Ling Y; Song T; Zhu L; Zhang B; Xu Q; Hu C; Bian XW; He X; Zhong H
Proc Natl Acad Sci U S A; 2014 Feb; 111(5):E601-10. PubMed ID: 24449872
[TBL] [Abstract][Full Text] [Related]
33. Association of ERα-36 expression with the de novo resistance of tamoxifen in ER-positive breast cancer.
Juliansyah A; Rahman S; Indra I; Nelwan B; Prihantono P
Breast Dis; 2021; 40(S1):S123-S127. PubMed ID: 34057127
[TBL] [Abstract][Full Text] [Related]
34. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
[No Abstract] [Full Text] [Related]
35. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
37. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
38. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
39. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]